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New peptide-based diagnostic and therapeutic approaches hold
promise for highly selective targeting of cancer leading to more
precise and effective diagnostic and therapeutic modalities. An
important feature of these approaches is to reach the tumor tissue
while limiting or minimizing the dose to normal organs. In this
context, efforts to design and engineer materials with optimal
in vivo targeting and clearance properties are important. This Data
In Brief article reports on biodistribution and radiation absorbed
dose proﬁle of a novel high afﬁnity radiopeptide speciﬁc for bone
marrow-derived tumor vasculature. Background information on
the design, preparation, and in vivo characterization of this
peptide-based targeted radiodiagnostic is described in the article
“Synthesis and comparative evaluation of novel 64Cu-labeled high
afﬁnity cell-speciﬁc peptides for positron emission tomography of
tumor vasculature” (Merrill et al., 2016) [1]. Here we report bio-
distribution measurements in mice and calculate the radiation
absorbed doses to normal organs using a modiﬁed Medicalvier Inc. This is an open access article under the CC BY license
/j.biomaterials.2016.01.031
dical Engineering, North Carolina State University, Raleigh, NC 27695, USA.
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for physical and geometric factors and cross-organ beta doses.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations TableSubject area Chemistry in radiology
ore speciﬁc sub-
ject areaMaterials Scienceype of data Tables
ow data was
acquiredDirect collection of tissues from mice at different time-points post-injectionata format Analyzed data
xperimental
factorsNovel radiopeptide targeting tumor vasculature was administered intrave-
nously into micexperimental
featuresBiodistribution data were analyzed using more precise method accounting for
the small size of the murine organs and for the type of radionuclide emissionsata source location USA
ata accessibility Data is provided within this articleD
Value of the data
 The data reported here demonstrate how mouse tissue distribution measurements can be used to
determine radiation absorbed dose to normal mouse tissues and organs.
 Using this improved dosimetric approach that incorporates cross-organ beta doses permits reﬁned
and more accurate estimates of the radiation absorbed dose to normal tissues.
 Accurate absorbed dose estimates which account for the size (mass and dimensions) of the murine
organs or lesions as well as for the decay characteristics of the radionuclide are essential in eval-
uating novel radiodiagnostic and radiotherapeutic compounds.
 Cross-organ contributions may be very important for understanding differences in biologic effects
in tumors and micro metastasis in different organs.
 The data presented here can be of value to material scientists and engineers to more accurately
evaluate radiation safety proﬁles of new radiodiagnostic and radiopharmaceutic compositions
in mice.1. Data
Previous reports have shown that the high afﬁnity, high speciﬁcity FHT-peptide selected by screening of
a bacteriophage library [2,3], when labeled with the positron emission tomography radionuclide, copper-64,
64Cu, can speciﬁcally image bone marrow-derived tumor vasculature [1,4]. In this Data in Brief article we
provide data on biodistribution of this radiopeptide at 1 h, 4 h, and 24 h post- injection in a subcutaneous
Lewis lung carcinoma tumor model (Table 1). From the biodistribution data, using a geometric model that
accounts for the small size of the murine organs [5] and for the decay characteristics of the 64Cu radio-
nuclide [6], we have determined the speciﬁc accumulated activity in mouse organs over time (Table 2) and
we have calculated radiation absorbed dose in the liver, spleen, kidney, lungs, heart, stomach, small and
large intestine, thyroid, pancreas, and murine carcass (Table 3).
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The animal protocols were approved by the University of North Carolina at Chapel Hill Institutional
Animal Care and Use Committee.2.1. Biodistribution in tumor bearing C57BL/6 mice
Approximately 0.74 MBq of 64Cu-labeled peptide in a total volume of 150 μl of saline was injected
under anesthesia intravenously via a catheter in the tail vein in Lewis lung carcinoma (LLC) tumor-
bearing C57BL/6 mice (n¼3 per time point) as described in Ref. [1]. At 1 h, 4 h, or 24 h post-injection
mice were sacriﬁced under anesthesia and liver, spleen, kidney, lungs, heart, stomach, small and large
intestines, thyroid, pancreas, and muscle were harvested. The organs were weighted and their
radioactivity was measured in an automated gamma counter (WIZARD2, Perkin Elmer Life Sciences,
Gaithersburg, MD). Radioactivity concentrations were calibrated, decay-corrected, and expressed as
percentage of injected dose per gram tissue (%ID/g). The percentage of injected dose per gram carcass
was approximated from radioactivity in a sample of muscle. The biodistribution data at different time
points post injection are presented in Table 1.Table 2
Speciﬁc accumulated activity in mouse organs over time. Values in MBq s/g per MBq injected dose, presented as mean7SD
(n¼3).
Organ Time interval post-injection Total activity
0–1 h 1–4 h 4–24 h 24 h-inﬁnity MBq s/g MBq
Liver 56.876.8 147.6731.5 617.37209.5 335.07129.6 1156.77248.4
Spleen 18.274.8 71.3724.7 357.67158.2 143.0719.1 590.27161.4
Kidney 193.6724.8 416.8787.6 1214.67512.2 431.47175.2 2256.57557.3
Lungs 60.9716.6 137.3737.6 461.77164.6 215.97100.7 875.87197.2
Heart 10.473.9 32.979.4 178.1745.2 118.1729.2 339.5754.8
Stomach 8.073.0 96.2721.0 573.57138.3 132.4718.2 810.07141.1
Small Intestine 39.0724.6 97.8753.4 387.97205.0 201.8746.8 726.57218.4
Large Intestine 21.4712.8 78.6731.1 410.97146.0 206.6759.8 717.57161.3
Thyroid 5.571.7 32.376.9 173.2743.6 48.8721.6 259.8749.2
Pancreas 20.677.2 38.9713.6 128.3728.5 102.4723.2 290.2739.8
Carcass 3.370.8 10.174.5 50.6734.1 29.5732.9 93.4747.7
Table 1
Biodistribution of 64Cu-labeled FHT-peptide in C57BL/6 mice. Values are presented as mean7SD (%ID/g) (n¼3).
Organ Time post-injection
1 h 4 h 24 h
Liver 1.6170.21 1.5070.67 0.8670.34
Spleen 0.5770.14 0.9670.54 0.3770.06
Kidney 5.2870.82 3.3771.77 1.1270.48
Lungs 1.6870.58 1.1870.54 0.5670.27
Heart 0.3170.14 0.3970.15 0.3070.08
Stomach 0.4170.07 1.7370.48 0.3470.06
Small Intestine 1.1070.86 0.9670.71 0.5270.13
Large Intestine 0.6670.44 1.0370.48 0.5370.17
Thyroid 0.2070.06 0.5070.14 0.1370.06
Pancreas 0.5570.25 0.2570.09 0.2670.07
Carcass 0.1070.02 0.1270.10 0.0470.02
Table 3
Radiation absorbed doses in C57Bl6 mice calculated using biodistribution data and the cross-organ mouse model [6]. Values in
mGy per MBq injected dose.
Target organ, k Source organ, h Total
dose
Liver Spleen Kidney Lungs Heart Stomach Small
intestine
Large
intestine
Thyroid Pancreas Carcass mGy/MBq
Liver 21.01 0.00 0.23 0.05 0.01 0.13 0.02 0.00 0.00 0.64 0.03 21.48
Spleen 0.00 9.28 0.96 0.00 0.00 0.95 0.00 0.00 0.00 0.15 0.00 11.83
Kidney 0.28 0.15 38.72 0.00 0.00 0.27 0.10 0.02 0.00 0.00 0.00 39.68
Lungs 1.13 0.00 0.00 13.81 0.18 0.11 0.00 0.00 0.00 0.00 0.13 15.36
Heart 0.21 0.00 0.00 1.28 5.82 0.00 0.00 0.00 0.00 0.06 0.00 7.30
Stomach 0.18 0.24 0.31 0.05 0.00 14.51 0.06 0.00 0.00 0.00 0.00 15.40
Small Intestine 0.27 0.00 0.41 0.00 0.00 0.08 13.18 0.37 0.00 0.00 0.07 14.38
Large Intestine 0.14 0.00 0.26 0.00 0.00 0.02 0.33 12.75 0.00 0.00 0.00 13.51
Thyroid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.48 0.00 0.29 3.77
Pancreas 0.00 0.45 0.83 0.00 0.00 0.23 0.00 0.00 0.00 4.37 0.00 5.89
Carcass 0.04 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.01 0.00 1.76 1.90
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The method for calculating the dose from internal beta emitters in mice was developed for 90Y by
Hui et al. [5] and extended to other radionuclides, including 64Cu, by Miller et al. [6]. This method
includes cross-organ contributions from beta particles and ignores the dose from photons which are
more likely to completely escape the mouse. The absorbed dose, D, to a target organ, k, from a source
organ, h, is given by:
D rk’rhð Þ ¼ KEβφβ rk’rhð Þ
A

h
mh
 !
mh
mk
 
where K is a unit conversion constant, Eβ is the average energy of emitted beta particles (0.121 MeV
for 64Cu), φβ rk’rhð Þ is the fraction of energy emitted in source organ h that is absorbed in target organ
k, A

h
mh
is the speciﬁc accumulated activity in the source organ h, and mk is the mass of the target organ
k. Absorbed fractions in mouse organs for 64Cu are taken from Ref. [6].
Accumulated activity is found from the gamma counting biodistribution data collected at 1, 4 and
24 h post-injection converted to speciﬁc activity in Bq/g and normalized to an injected dose of 1 MBq.
These values are plotted with respect to time of sacriﬁce to create a time-activity curve and the
accumulated activity is found by integrating this curve. Integration was performed by the trapezoidal
method up to the 24 h time point. Activity trapped in an organ after 24 h was considered to be cleared
only by the physical decay of 64Cu with a half-life of 12.701 h. The accumulated activity from this
period was found by integrating the exponential decay to inﬁnity:
A

h;t424h ¼ A24h
Z 1
t ¼ 24h
exp  0:693
12:701h
t24hð Þ
 
dt
The speciﬁc accumulated activity in each organ for each time interval measured and over all time
is summarized in Table 2. The accumulated activity contained in each source organ is found by
multiplying the accumulated activity per gram by the average mass of the organ.
The source-to-target doses for each MBq of injected activity are summarized in Table 3. For each
target organ, the total dose is found by summing the contributions from all source organs:
D rk’rhð Þ ¼ KEβ
X
h
φβ rk’rhð Þ
A

h
mh
 !
mh
mk
 
J.R. Merrill et al. / Data in Brief 7 (2016) 480–484484The ﬁnal column of Table 3 displays these total target organ absorbed doses in mGy per MBq of
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